Unibest

Pharmaceutical intermediates

Carfilzomib Intermediates

5 pharmaceutical intermediates for Carfilzomib. Indication: Multiple myeloma.

提交项目All intermediates

About Carfilzomib

Originator
Onyx Pharmaceuticals Inc
Indication
Multiple myeloma
Approved Date
07/20/2012

Available intermediates

5 intermediates currently listed for Carfilzomib. Request specifications, documentation or a quotation for any item below.

Carfilzomib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
CarbaMic acid, N-[(1S)-3-Methyl-1-[[(2R)-2-Methyl-2-oxiranyl]carbonyl]butyl]-, 1,1-diMethylethyl ester247068-82-2//
1-Pentanone, 2-aMino-4-Methyl-1-[(2R)-2-Methyloxiranyl]-, (2S)-, trifluoroacetate (9CI)247068-85-5//
(alphaS)-alpha-Aminobenzenebutanoyl-L-leucyl-L-phenylalanine methyl ester868539-98-4//
(alphaS)-alpha-Aminobenzenebutanoyl-L-leucyl-L-phenylalanine methyl ester mono(trifluoroacetate)868539-99-5//
(alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-L-phenylalanine methyl ester1140908-89-9//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCanagliflozinCangrelor TetrasodiumCapivasertib Capmatinib Hydrochloride

Building toward Carfilzomib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →